Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL)

“…Moreover, pamidronate may also ameliorate pain scores and musculoskeletal function in patients with AVN occurring as a complication of childhood ALL therapy, even though objective radiologic benefits could not be demonstrated so far [70][71][72].…”

Section: Therapeutic Issuesmentioning

confidence: 99%

“…Based on the good results obtained in patients with osteogenesis imperfecta, drugs such as the bisphosphonates can clearly inhibit bone resorption when used in children either receiving anti-leukemic therapy or many years after the completion of therapy, even though the great experience is during ALL chemotherapy [23,[65][66][67][68][69][70][71][72].…”

Section: Therapeutic Issuesmentioning

confidence: 99%

Are Survivors of Childhood Acute Lymphoblastic Leukemia at Increased Risk for Low Bone Mass?

Siviero-Miachon¹,

Lee²,

Guerra‐Júnior

et al. 2014

J Leuk

View full text Add to dashboard Cite

Acute lymphoblastic leukemia is the most prevalent cancer in children. As an increasing number of cancer survivors reaches adulthood, there may be consequences of the treatment, and there is an issue if low bone mass might be included as a significant late effect. Acute lymphoblastic leukemia patients may have their bone mass compromised during therapy and many years after its withdrawal, but the degree of bone mass decline or recovery are not well elucidated to date. Survivors of stem cell transplantation for leukemia have additional risk factors for bone loss and should be evaluated with caution. Our target is to make a warning about the difficulties in assessing and interpreting bone mass in children and adolescents, the limitations in this assessment in acute lymphoblastic leukemia young survivors (including survivors of stem cell transplantation), the possibility of misdiagnoses, the reasons (if there are any) of low bone mass in this particular group of cancer survivors, as well as consider the therapeutic issues available.

show abstract

“…The current evidence is Level IV and limited to small case series and observational studies (Table 1). Of the articles reviewed, the etiology of childhood femoral head ischemia was posttraumatic in one study [40] and high-dose corticosteroid/ chemotherapy-induced after treatment for childhood leukemia or malignancy in two studies [21,32]. All three studies were subject to selection bias.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 61 clinical articles were excluded based on these criteria, leaving six articles for full review by three reviewers (HKWK, DGL, MLY). Of these six articles, three did not address clinical or radiographic outcome of BP therapy and were excluded, leaving three articles for analysis [21,32,40]. Data were extracted by one reviewer (MLY) into prearranged summary tables.…”

Section: Search Strategy and Criteriamentioning

confidence: 99%

Evidence for Using Bisphosphonate to Treat Legg-Calvé-Perthes Disease

Young

Little

Kim

2012

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background The rationale for using bisphosphonate (BP) therapy for Legg-Calvé-Perthes disease (LCPD) is the potential to prevent substantial femoral head deformity during the fragmentation phase by inhibiting osteoclastic bone resorption. However, it is unclear whether BP therapy decreases femoral head deformity. Questions/purposes In this systematic review, we answered the following questions: (1) Does bisphosphonate (BP) therapy decrease femoral head deformity and improve pain and function in LCPD or other juvenile osteonecrotic conditions? And (2) does BP therapy decrease femoral head deformity in experimental studies of juvenile femoral head osteonecrosis? Methods We searched the literature from 1966 to 2011 for clinical and experimental studies on BP therapy for juvenile femoral head osteonecrosis. Studies specifically addressing clinical and/or radiographic/histologic outcomes pertaining to pain and function and femoral head morphology were analyzed.

show abstract

Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL)

Cited by 56 publications

References 23 publications

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

Are Survivors of Childhood Acute Lymphoblastic Leukemia at Increased Risk for Low Bone Mass?

Evidence for Using Bisphosphonate to Treat Legg-Calvé-Perthes Disease

Contact Info

Product

Resources

About